Eric J Lenze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2620370/publications.pdf

Version: 2024-02-01

281 papers 13,762 citations

25034 57 h-index 104 g-index

291 all docs

291 docs citations

times ranked

291

13904 citing authors

#	Article	IF	CITATIONS
1	Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: A systematic review and meta-analysis. Journal of Telemedicine and Telecare, 2022, 28, 547-558.	2.7	23
2	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	2.2	31
3	Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement. Biological Psychiatry Global Open Science, 2022, 2, 127-135.	2.2	2
4	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health, 2022, 10, e42-e51.	6.3	296
5	Mental Health Clinical Research Innovations during the COVID-19 Pandemic. Psychiatric Clinics of North America, 2022, 45, 179-189.	1.3	4
6	Modified Application of Cardiac Rehabilitation in Older Adults (MACRO) Trial: Protocol changes in a pragmatic multi-site randomized controlled trial in response to the COVID-19 pandemic. Contemporary Clinical Trials, 2022, 112, 106633.	1.8	4
7	Differential Placebo Responses for Pharmacotherapy and Neurostimulation in Late-Life Depression. Neuromodulation, 2022, , .	0.8	0
8	Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. Journal of the Neurological Sciences, 2022, 434, 120152.	0.6	11
9	Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSâ€'CoVâ€'2 Infection: A Revie of Current Evidence― Drugs, 2022, 82, 353.	^{?W} 10.9	0
10	Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. Pharmacopsychiatry, 2022, 55, 24-29.	3.3	14
11	Covariance and Correlation Analysis of Resting State Functional Magnetic Resonance Imaging Data Acquired in a Clinical Trial of Mindfulness-Based Stress Reduction and Exercise in Older Individuals. Frontiers in Neuroscience, 2022, 16, 825547.	2.8	4
12	Ecological Momentary Assessment of Real-World Functional Behaviors in Individuals With Stroke: A Longitudinal Observational Study. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1327-1337.	0.9	2
13	Association of a Perioperative Multicomponent Fall Prevention Intervention With Falls and Quality of Life After Elective Inpatient Surgical Procedures. JAMA Network Open, 2022, 5, e221938.	5.9	3
14	Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial. American Journal of Geriatric Psychiatry, 2022, 30, 994-1002.	1.2	2
15	Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization. JAMA Network Open, 2022, 5, e226269.	5.9	48
16	"What else can we do?â€â€"Provider perspectives on treatmentâ€resistant depression in late life. Journal of the American Geriatrics Society, 2022, 70, 1190-1197.	2.6	4
17	Repurposing fluvoxamine, and other psychiatric medications, for <scp>COVID</scp> â€19 and other conditions. World Psychiatry, 2022, 21, 314-315.	10.4	4
18	Using Implementation Science to Guide the Process of Adapting a Patient Engagement Intervention for Inpatient Spinal Cord Injury/Disorder Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2022, , .	0.9	0

#	Article	IF	Citations
19	Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome. JAMA Network Open, 2022, 5, e2219678.	5.9	8
20	Older molecular brain age in severe mental illness. Molecular Psychiatry, 2021, 26, 3646-3656.	7.9	23
21	Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials. Topics in Stroke Rehabilitation, 2021, 28, 289-320.	1.9	8
22	Surgical Complications in Older Adults Predict Decline in Self-Perceived Cognitive Function in the Ensuing Year: A Cohort Study. American Journal of Geriatric Psychiatry, 2021, 29, 352-361.	1.2	1
23	Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology, 2021, 238, 1157-1169.	3.1	9
24	Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. Journal of Clinical Psychopharmacology, 2021, 41, 31-35.	1.4	7
25	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	4.8	22
26	Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. Journal of Psychiatry and Neuroscience, 2021, 46, E97-E110.	2.4	19
27	Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy. Journal of Psychiatry and Neuroscience, 2021, 46, E88-E96.	2.4	7
28	Perioperative Mental Health in Older Adults: New Research on Epidemiology and Outcomes. American Journal of Geriatric Psychiatry, 2021, 29, 1222-1224.	1.2	0
29	Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time. Open Forum Infectious Diseases, 2021, 8, ofab090.	0.9	20
30	Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen. Clinical Neurophysiology, 2021, 132, 977-983.	1.5	3
31	Transcranial magnetic stimulation indices of cortical excitability enhance the prediction of response to pharmacotherapy in late-life depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.5	1
32	Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVIDâ€19: An Observational Multicenter Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1498-1511.	4.7	59
33	Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Molecular Psychiatry, 2021, 26, 7098-7099.	7.9	38
34	Ketamine for Depression in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 914-916.	1.2	5
35	Effect of electroencephalogram-guided anaesthesia administration on 1-yr mortality: follow-up of a randomised clinical trial. British Journal of Anaesthesia, 2021, 127, 386-395.	3.4	6
36	Comparing stress prediction models using smartwatch physiological signals and participant self-reports. Computer Methods and Programs in Biomedicine, 2021, 208, 106207.	4.7	12

#	Article	IF	Citations
37	Executive Function Moderates Functional Outcomes of Engagement Strategies During Rehabilitation in Older Adults. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 635-642.	1.4	2
38	COVID-19 Clinical Trials: A Voice From the Front Lines. Narrative Inquiry in Bioethics, 2021, 11, 16-19.	0.1	0
39	Activity Level and Intensity of Older Adults in Skilled Nursing Rehabilitation Measured via Actigraphy. Journal of Geriatric Physical Therapy, 2021, 44, 45-50.	1.1	4
40	Going remote: Implementing digital research methods at an academic medical center during COVID-19. Journal of Clinical and Translational Science, 2021, 5, e189.	0.6	7
41	Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial. Mindfulness, 2021, 12, 1-13.	2.8	17
42	Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. Drugs, 2021, 81, 2081-2089.	10.9	28
43	Neuroticism predicts fear of falling after hip fracture. International Journal of Geriatric Psychiatry, 2020, 35, 498-506.	2.7	8
44	Mood Disorders and Dementia: Time for Action. American Journal of Geriatric Psychiatry, 2020, 28, 542-544.	1.2	0
45	The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs, 2020, 34, 1133-1147.	5.9	44
46	Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample. Clinical Trials, 2020, 17, 581-594.	1.6	13
47	iTBS to Relieve Depression and Executive Dysfunction in Older Adults: An Open Label Study. American Journal of Geriatric Psychiatry, 2020, 28, 1195-1199.	1.2	10
48	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2292.	7.4	421
49	Positive information facilitates response inhibition in older adults only when emotion is task-relevant. Cognition and Emotion, 2020, 34, 1632-1645.	2.0	12
50	Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults. Journal of Psychopharmacology, 2020, 34, 1112-1118.	4.0	5
51	mHealth Assessment and Intervention of Depression and Anxiety in Older Adults. Harvard Review of Psychiatry, 2020, 28, 203-214.	2.1	33
52	The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults. Journal of Clinical Psychopharmacology, 2020, 40, 553-559.	1.4	7
53	Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation. Clinical Neurophysiology, 2020, 131, 2817-2825.	1.5	4
54	Pharmacological Treatments for Tinnitusâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1109.	7.4	1

#	Article	IF	CITATIONS
55	Stereoselective Steadyâ€State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. Clinical Pharmacology and Therapeutics, 2020, 108, 1036-1048.	4.7	2
56	Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study. American Journal of Geriatric Psychiatry, 2020, 28, 924-932.	1,2	108
57	Action at a Distance: Geriatric Research during a Pandemic. Journal of the American Geriatrics Society, 2020, 68, 922-925.	2.6	91
58	A Framework for Advancing Precision Medicine in Clinical Trials for Mental Disorders. JAMA Psychiatry, 2020, 77, 663.	11.0	36
59	A Qualitative Study of Perioperative Depression and Anxiety in Older Adults. American Journal of Geriatric Psychiatry, 2020, 28, 1107-1118.	1.2	18
60	Tinnitus. JAMA - Journal of the American Medical Association, 2020, 323, 1497.	7.4	29
61	Does patient expectancy account for the cognitive and clinical benefits of mindfulness training in older adults?. International Journal of Geriatric Psychiatry, 2020, 35, 626-632.	2.7	8
62	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109867.	4.8	8
63	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. American Journal of Geriatric Psychiatry, 2020, 28, 609-629.	1.2	18
64	Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. American Journal of Psychiatry, 2020, 177, 548-555.	7.2	31
65	Preoperative Cognitive Abnormality, Intraoperative Electroencephalogram Suppression, and Postoperative Delirium. Anesthesiology, 2020, 132, 1458-1468.	2.5	36
66	A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment. JMIR MHealth and UHealth, 2020, 8, e18609.	3.7	8
67	"What Were You Before the War?―Repurposing Psychiatry During the COVID-19 Pandemic. Journal of Clinical Psychiatry, 2020, 81, .	2.2	31
68	Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders. Journal of Clinical Psychiatry, 2020, 81, .	2.2	5
69	Moment-to-Moment Associations Between Depressive Symptoms and Daily Functioning Among Stroke Survivors: An Ecological Momentary Assessment (EMA) Study. American Journal of Occupational Therapy, 2020, 74, 7411500034p1-7411500034p1.	0.3	1
70	Cross-Lagged Panel Approach to Understanding Depression and Functional Status in the First Year After Stroke. American Journal of Occupational Therapy, 2020, 74, 7411510317p1-7411510317p1.	0.3	0
71	Crossover to Bilateral Repetitive Transcranial Magnetic Stimulation. Journal of ECT, 2019, 35, 3-5.	0.6	9
72	Cognitive Training for Optimizing Perioperative Brain Health. American Journal of Geriatric Psychiatry, 2019, 27, 1228-1231.	1.2	2

#	Article	IF	Citations
73	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. Journal of Anxiety Disorders, 2019, 68, 102149.	3.2	36
74	Comorbid anxiety in lateâ€life depression: Relationship with remission and suicidal ideation on venlafaxine treatment. Depression and Anxiety, 2019, 36, 1125-1134.	4.1	31
75	Effect of Enhanced Medical Rehabilitation on Functional Recovery in Older Adults Receiving Skilled Nursing Care After Acute Rehabilitation. JAMA Network Open, 2019, 2, e198199.	5.9	28
76	Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. NeuroImage: Clinical, 2019, 21, 101679.	2.7	11
77	Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery. JAMA - Journal of the American Medical Association, 2019, 321, 473.	7.4	291
78	Emotional Response Inhibition Is Greater in Older Than Younger Adults. Frontiers in Psychology, 2019, 10, 961.	2.1	8
79	Antidepressant Treatment for Lateâ€Life Depression: Considering Risks and Benefits. Journal of the American Geriatrics Society, 2019, 67, 1555-1556.	2.6	5
80	Obsessions are strongly related to eating disorder symptoms in anorexia nervosa and atypical anorexia nervosa. Eating Behaviors, 2019, 34, 101298.	2.0	26
81	An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression. Neuropsychopharmacology, 2019, 44, 1659-1666.	5.4	9
82	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 439-447.	1.3	10
83	Feasibility of Intensive Ecological Sampling of Tinnitus in Intervention Research. Otolaryngology - Head and Neck Surgery, 2019, 161, 485-492.	1.9	7
84	Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. American Journal of Geriatric Psychiatry, 2019, 27, 1138-1152.	1.2	40
85	Diagnostic, clinical, and personality correlates of food anxiety during a food exposure in patients diagnosed with an eating disorder. Eating and Weight Disorders, 2019, 24, 1079-1088.	2.5	13
86	Pride and Prejudice in the Treatment of Depression and Anxiety in Acutely III Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 391-394.	1.2	3
87	Assessment and treatment of major depression in older adults. Handbook of Clinical Neurology <i> </i> Edited By P J Vinken and G W Bruyn, 2019, 167, 429-435.	1.8	47
88	A qualitative study of older adults' perspectives on initiating exercise and mindfulness practice. BMC Geriatrics, 2019, 19, 354.	2.7	27
89	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 30.	5.3	32
90	Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 1164-1174.	4.7	10

#	Article	IF	Citations
91	The role of depression pharmacogenetic decision support tools in shared decision making. Journal of Neural Transmission, 2019, 126, 87-94.	2.8	21
92	When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials. JMIR Mental Health, 2019, 6, e11845.	3.3	26
93	Predicting Remission in Late-Life Major Depression. Journal of Clinical Psychiatry, 2019, 80, .	2.2	21
94	Meal and snack-time eating disorder cognitions predict eating disorder behaviors and vice versa in a treatment seeking sample: A mobile technology based ecological momentary assessment study. Behaviour Research and Therapy, 2018, 105, 36-42.	3.1	31
95	Cognitive Training for Older Adults: What Works?. Journal of the American Geriatrics Society, 2018, 66, 645-647.	2.6	8
96	Ability of postoperative delirium to predict intermediate-term postoperative cognitive function in patients undergoing elective surgery at an academic medical centre: protocol for a prospective cohort study. BMJ Open, 2018, 8, e017079.	1.9	5
97	Depression and Functional Impairment: A Pernicious Pairing in Older Adults. American Journal of Geriatric Psychiatry, 2018, 26, 73-74.	1.2	3
98	Specific depressive symptoms predict remission to aripiprazole augmentation in lateâ€ife treatment resistant depression. International Journal of Geriatric Psychiatry, 2018, 33, e330-e335.	2.7	6
99	Achieving Milestones as a Prerequisite for Proceeding With a Clinical Trial. Anesthesia and Analgesia, 2018, 126, 1851-1858.	2.2	8
100	Effects of Cable News Watching on Older Adults' Physiological and Self-Reported Stress and Cognitive Function. International Journal of Aging and Human Development, 2018, 87, 111-123.	1.6	5
101	The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment. Journal of Psychiatric Research, 2018, 96, 162-166.	3.1	4
102	Cognitive Improvement in Older Adults in the Year After Hip Fracture: Implications for Brain Resilience in Advanced Aging. American Journal of Geriatric Psychiatry, 2018, 26, 1119-1127.	1.2	7
103	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. Pharmacogenomics, 2018, 19, 1269-1284.	1.3	16
104	Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation. Journal of Psychiatric Research, 2018, 105, 63-70.	3.1	6
105	Reduced GABAergic cortical inhibition in aging and depression. Neuropsychopharmacology, 2018, 43, 2277-2284.	5.4	34
106	Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol. Frontiers in Psychiatry, 2018, 9, 171.	2.6	12
107	Scientific Biography of a Mid-Career Physician-Scientist: Getting by With Help From My Friends. American Journal of Geriatric Psychiatry, 2018, 26, 998-1004.	1.2	1
108	Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 828-834.	1.2	5

#	Article	IF	Citations
109	Childhood Trauma Is Associated With Poorer Cognitive Performance in Older Adults. Journal of Clinical Psychiatry, 2018, 79, 16m11021.	2.2	21
110	Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression. Journal of Clinical Psychiatry, 2018, 79, .	2.2	17
111	Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial. Journal of Clinical Psychiatry, 2018, 79, .	2.2	4
112	Treatment Emergent Suicidal Ideation in depressed older adults. International Journal of Geriatric Psychiatry, 2017, 32, 596-604.	2.7	6
113	Immunological biomarkers associated with brain structure and executive function in lateâ€ife depression: exploratory pilot study. International Journal of Geriatric Psychiatry, 2017, 32, 692-699.	2.7	33
114	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. American Journal of Psychiatry, 2017, 174, 468-475.	7.2	41
115	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. JAMA Psychiatry, 2017, 74, 501.	11.0	236
116	Predictors of Posttraumatic Stress Symptoms and Association with Fear of Falling After Hip Fracture. Journal of the American Geriatrics Society, 2017, 65, 1251-1257.	2.6	19
117	Evaluation of Ecological Momentary Assessment for Tinnitus Severity. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 700.	2.2	29
118	Bone Turnover with Venlafaxine Treatment in Older Adults with Depression. Journal of the American Geriatrics Society, 2017, 65, 2057-2063.	2.6	14
119	Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet, The, 2017, 390, 267-275.	13.7	346
120	Alternative Facts? Antidepressants and Falls in Older Adults. American Journal of Geriatric Psychiatry, 2017, 25, 1337-1338.	1.2	1
121	Potentially Inappropriate Medications and the Time to Full Functional Recovery After Hip Fracture. Drugs and Aging, 2017, 34, 723-728.	2.7	27
122	Effect of Metabolic Syndrome on Lateâ€Life Depression: Associations with Disease Severity and Treatment Resistance. Journal of the American Geriatrics Society, 2017, 65, 2651-2658.	2.6	27
123	Fear of food prospectively predicts drive for thinness in an eating disorder sample recently discharged from intensive treatment. Eating Behaviors, 2017, 27, 45-51.	2.0	28
124	Gray matter regions statistically mediating the crossâ€sectional association of eotaxin and setâ€shifting among older adults with major depressive disorder. International Journal of Geriatric Psychiatry, 2017, 32, 1226-1232.	2.7	6
125	Telephone-Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial. Journal of General Internal Medicine, 2017, 32, 245-255.	2.6	34
126	Mindfulness-Based Stress Reduction for Older Adults With Stress Disorders and Neurocognitive Difficulties. Journal of Clinical Psychiatry, 2017, 78, e734-e743.	2,2	93

#	Article	IF	Citations
127	Use of the Temperament and Character Inventory to Predict Response to Repetitive Transcranial Magnetic Stimulation for Major Depression. Journal of Psychiatric Practice, 2016, 22, 193-202.	0.7	17
128	Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences. Childhood Obesity, 2016, 12, 70-76.	1.5	16
129	Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial. BMJ Open, 2016, 6, e011505.	1.9	53
130	Enhanced Medical Rehabilitation: Effectiveness of a clinical training model. NeuroRehabilitation, 2016, 39, 481-498.	1.3	11
131	Trajectories of depressive symptoms after hip fracture. Psychological Medicine, 2016, 46, 1413-1425.	4.5	46
132	Feasibility and Acceptability of Smartphone Assessment in Older Adults with Cognitive and Emotional Difficulties. Journal of Technology in Human Services, 2016, 34, 209-223.	1.6	71
133	Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. American Journal of Geriatric Psychiatry, 2016, 24, 918-922.	1.2	11
134	Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study. American Journal of Geriatric Psychiatry, 2016, 24, 893-902.	1.2	12
135	Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias Journal of Abnormal Psychology, 2016, 125, 840-851.	1.9	221
136	Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. Journal of Psychiatric Research, 2016, 81, 112-118.	3.1	30
137	Fear of Falling after Hip Fracture: Prevalence, Course, and Relationship with One-Year Functional Recovery. American Journal of Geriatric Psychiatry, 2016, 24, 1228-1236.	1.2	50
138	Consequences of Anxiety in Aging and Cognitive Decline. American Journal of Geriatric Psychiatry, 2016, 24, 843-845.	1.2	4
139	Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression. Depression and Anxiety, 2016, 33, 1107-1113.	4.1	15
140	Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial Journal of Consulting and Clinical Psychology, 2016, 84, 345-352.	2.0	25
141	Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults. Journal of Psychiatric Research, 2016, 75, 116-123.	3.1	186
142	Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World Journal of Biological Psychiatry, 2016, 17, 230-238.	2.6	43
143	Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression. JAMA Psychiatry, 2016, 73, 329.	11.0	40
144	Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment. Journal of Psychiatric Research, 2016, 73, 96-101.	3.1	22

#	Article	IF	Citations
145	Clarifying the Behavioral Economics of Social Anxiety Disorder. Clinical Psychological Science, 2016, 4, 107-121.	4.0	10
146	Behavioral Weight Loss Treatment for Youth Treated With Antipsychotic Medications. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2016, 4, 96-104.	0.6	11
147	A new measure of fear of falling: psychometric properties of the fear of falling questionnaire revised (FFQ-R). International Psychogeriatrics, 2015, 27, 1121-1133.	1.0	27
148	Short-term affective recovery from hip fracture prospectively predicts depression and physical functioning Health Psychology, 2015, 34, 30-39.	1.6	8
149	Treating Anxiety Disorders in Older Adults. Harvard Review of Psychiatry, 2015, 23, 329-342.	2.1	69
150	d -Cycloserine Facilitation of Exposure Therapy Improves Weight Regain in Patients With Anorexia Nervosa. Journal of Clinical Psychiatry, 2015, 76, e787-e793.	2.2	50
151	A Novel Treatment for Tinnitus and Tinnitus-Related Cognitive Difficulties Using Computer-Based Cognitive Training and D-Cycloserine. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 18.	2.2	12
152	Ecological Momentary Assessment of Tinnitus Using Smartphone Technology. Otolaryngology - Head and Neck Surgery, 2015, 152, 897-903.	1.9	52
153	Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial. Psychiatric Services, 2015, 66, 1303-1311.	2.0	8
154	Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3418-3426.	3.6	2
155	Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 2404-2412.	13.7	229
156	Response to Stubbs's Letter to the Editor. American Journal of Geriatric Psychiatry, 2015, 23, 1098-1099.	1.2	0
157	Effects of Mindfulness Based Stress Reduction Therapy on Subjective Bother and Neural Connectivity in Chronic Tinnitus. Otolaryngology - Head and Neck Surgery, 2015, 152, 919-926.	1.9	60
158	Response to Mohler and Colleagues. Journal of the American Geriatrics Society, 2015, 63, 624-624.	2.6	1
159	Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults. JAMA Psychiatry, 2015, 72, 1021.	11.0	54
160	Solving the Geriatric Mental Health Crisis in the 21st Century. JAMA Psychiatry, 2015, 72, 967.	11.0	10
161	Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review. American Journal of Geriatric Psychiatry, 2015, 23, 1016-1028.	1.2	64
162	Association of Functional Polymorphisms from Brain-Derived Neurotrophic Factor and Serotonin-Related Genes with Depressive Symptoms after a Medical Stressor in Older Adults. PLoS ONE, 2015, 10, e0120685.	2.5	27

#	Article	IF	CITATIONS
163	Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults. Journal of Clinical Psychiatry, 2014, 75, e785-e793.	2.2	154
164	Patient Active Time During Therapy Sessions in Postacute Rehabilitation: Development and Validation of a New Measure. Physical and Occupational Therapy in Geriatrics, 2014, 32, 169-178.	0.4	16
165	Validation of the Ambivalent and Purposeful Engagement – Trait Measure. Anxiety, Stress and Coping, 2014, 27, 317-334.	2.9	2
166	Combining < scp > d < /scp > -cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke. Journal of Neurophysiology, 2014, 111, 2516-2524.	1.8	23
167	Mindfulnessâ€based stress reduction for older adults with worry symptoms and coâ€occurring cognitive dysfunction. International Journal of Geriatric Psychiatry, 2014, 29, 991-1000.	2.7	143
168	Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. International Journal of Geriatric Psychiatry, 2014, 29, 962-969.	2.7	16
169	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World Journal of Biological Psychiatry, 2014, 15, 404-410.	2.6	17
170	Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review. Journal of the American Geriatrics Society, 2014, 62, 1434-1441.	2.6	43
171	Common Selective Serotonin Reuptake Inhibitor Side Effects in Older Adults Associated with Genetic Polymorphisms in the Serotonin Transporter and Receptors: Data from a Randomized Controlled Trial. American Journal of Geriatric Psychiatry, 2014, 22, 971-979.	1.2	26
172	Dynamic Prediction of Treatment Response in Late-Life Depression. American Journal of Geriatric Psychiatry, 2014, 22, 167-176.	1.2	40
173	How bandwidth selection algorithms impact exploratory data analysis using kernel density estimation Psychological Methods, 2014, 19, 428-443.	3.5	16
174	Is There a Role for Antidepressant and Antipsychotic Pharmacogenetics in Clinical Practice in 2014?. Canadian Journal of Psychiatry, 2014, 59, 59-61.	1.9	4
175	Effect of Physical Activity, Social Support, and Skills Training on Late-Life Emotional Health: A Systematic Literature Review and Implications for Public Health Research. Frontiers in Public Health, 2014, 2, 213.	2.7	13
176	Serotoninâ€"norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption. Osteoporosis International, 2013, 24, 1741-1749.	3.1	38
177	Enhanced Medical Rehabilitation Is Feasible in a Skilled Nursing Facility: Preliminary Data on a Novel Treatment for Older Adults With Depression. American Journal of Geriatric Psychiatry, 2013, 21, 307.	1.2	8
178	Anxiety Disorders in Older Adults: Looking to DSM5 and Beyond…. American Journal of Geriatric Psychiatry, 2013, 21, 872-876.	1.2	47
179	Research to Reduce the Suicide Rate Among Older Adults: Methodology Roadblocks and Promising Paradigms. Psychiatric Services, 2013, 64, 586-589.	2.0	34
180	Antidepressant Medication Augmented With Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults. American Journal of Psychiatry, 2013, 170, 782-789.	7.2	79

#	Article	IF	Citations
181	Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. International Journal of Neuropsychopharmacology, 2013, 16, 279-288.	2.1	19
182	Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder. Aging and Mental Health, 2013 , 17 , $432-440$.	2.8	17
183	A HIGH-THROUGHPUT CLINICAL ASSAY FOR TESTING DRUG FACILITATION OF EXPOSURE THERAPY. Depression and Anxiety, 2013, 30, 631-637.	4.1	25
184	Lessons Learned Fromd-Cycloserine: The Promise and Limits of Drug Facilitation of Exposure Therapy. Journal of Clinical Psychiatry, 2013, 74, 415-416.	2.2	9
185	Reversal of SSRI-Associated Urinary Retention With Mirtazapine Augmentation. Journal of Clinical Psychopharmacology, 2012, 32, 434.	1.4	10
186	Measuring Treatment Fidelity in a Rehabilitation Intervention Study. American Journal of Physical Medicine and Rehabilitation, 2012, 91, 715-724.	1.4	71
187	Comorbid anxiety and depression: $b\tilde{A}^a$ te noire or quick fix?. British Journal of Psychiatry, 2012, 200, 179-181.	2.8	14
188	Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. Journal of the American Medical Directors Association, 2012, 13, 708-712.	2.5	50
189	Functional network dysfunction in anxiety and anxiety disorders. Trends in Neurosciences, 2012, 35, 527-535.	8.6	451
190	Treatmentâ€related alteration of cortisol predicts change in neuropsychological function during acute treatment of lateâ€life anxiety disorder. International Journal of Geriatric Psychiatry, 2012, 27, 454-462.	2.7	23
191	Improving recognition of late life anxiety disorders in <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition: observations and recommendations of the <i>Advisory Committee to the Lifespan Disorders Work Group</i> . International Journal of Geriatric Psychiatry, 2012, 27, 549-556.	2.7	80
192	Memantine for lateâ€life depression and apathy after a disabling medical event: a 12â€week, doubleâ€blind placeboâ€controlled pilot study. International Journal of Geriatric Psychiatry, 2012, 27, 974-980.	2.7	49
193	Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder. British Journal of Psychiatry, 2011, 199, 211-218.	2.8	87
194	Anxiety Disorders: New Developments in Old Age. American Journal of Geriatric Psychiatry, 2011, 19, 301-304.	1.2	33
195	Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: A Placebo-Controlled Evaluation of Escitalopram. American Journal of Geriatric Psychiatry, 2011, 19, 482-490.	1.2	109
196	Treating Depression in Older Adults with Dementia. Journal of the American Geriatrics Society, 2011, 59, 754-755.	2.6	6
197	Inflammatory Cytokine Levels and Depressive Symptoms in Older Women in the Year After Hip Fracture: Findings from the Baltimore Hip Studies. Journal of the American Geriatrics Society, 2011, 59, 2249-2255.	2.6	23
198	Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study. International Journal of Geriatric Psychiatry, 2011, 26, 869-875.	2.7	21

#	Article	IF	Citations
199	Altered cerebral blood flow patterns associated with pathologic worry in the elderly. Depression and Anxiety, 2011, 28, 202-209.	4.1	65
200	Maintenance Treatment of Depression in Old Age. Archives of General Psychiatry, 2011, 68, 51.	12.3	145
201	Enhanced Medical Rehabilitation Is Feasible in a Skilled Nursing Facility. American Journal of Geriatric Psychiatry, 2011, , 1.	1.2	2
202	A lifespan view of anxiety disorders. Dialogues in Clinical Neuroscience, 2011, 13, 381-399.	3.7	169
203	Relation of Serotonin Transporter Genetic Variation to Efficacy of Escitalopram for Generalized Anxiety Disorder in Older Adults. Journal of Clinical Psychopharmacology, 2010, 30, 672-677.	1.4	23
204	Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy <i>versus</i> escitalopram with depression care management. International Journal of Geriatric Psychiatry, 2010, 25, 1134-1141.	2.7	43
205	Anxiety disorders in older adults: a comprehensive review. Depression and Anxiety, 2010, 27, 190-211.	4.1	514
206	Cognitive and Affective Predictors of Rehabilitation Participation After Stroke. Archives of Physical Medicine and Rehabilitation, 2010, 91, 203-207.	0.9	140
207	Escitalopram Treatment of Generalized Anxiety Disorder in Older Adultsâ€"Reply. JAMA - Journal of the American Medical Association, 2009, 301, 1987.	7.4	2
208	Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in lateâ€life anxiety disorders. International Journal of Geriatric Psychiatry, 2009, 24, 1-14.	2.7	50
209	fMRI activation in lateâ€ife anxious depression: a potential biomarker. International Journal of Geriatric Psychiatry, 2009, 24, 820-828.	2.7	37
210	The utility of the Generalized Anxiety Disorder Severity Scale (GADSS) with older adults in primary care. Depression and Anxiety, 2009, 26, E10-E15.	4.1	16
211	High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depression and Anxiety, 2009, 26, 266-272.	4.1	29
212	Use of the Lateâ€Life Function and Disability Instrument to Assess Disability in Major Depression. Journal of the American Geriatrics Society, 2009, 57, 1612-1619.	2.6	32
213	Patient Participation and Physical Activity During Rehabilitation and Future Functional Outcomes in Patients After Hip Fracture. Archives of Physical Medicine and Rehabilitation, 2009, 90, 618-622.	0.9	74
214	The Burden of Late-Life Generalized Anxiety Disorder: Effects on Disability, Health-Related Quality of Life, and Healthcare Utilization. American Journal of Geriatric Psychiatry, 2009, 17, 473-482.	1,2	197
215	Aripiprazole Prescribing Patterns and Side Effects in Elderly Psychiatric Inpatients. Journal of Psychiatric Practice, 2009, 15, 150-153.	0.7	10
216	Apathy After Hip Fracture: A Potential Target for Intervention to Improve Functional Outcomes. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 271-278.	1.8	15

#	Article	IF	Citations
217	Escitalopram for Older Adults With Generalized Anxiety Disorder. JAMA - Journal of the American Medical Association, 2009, 301, 295.	7.4	107
218	Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression. Journal of Clinical Psychiatry, 2009, 70, 208-213.	2.2	49
219	Depressive symptoms in late life: associations with apathy, resilience and disability vary between youngâ€old and oldâ€old. International Journal of Geriatric Psychiatry, 2008, 23, 238-243.	2.7	133
220	Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture. Journal of Affective Disorders, 2008, 111, 61-66.	4.1	32
221	Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology, 2008, 33, 773-781.	2.7	177
222	Generalized Anxiety Disorder Severity Scale Validation in Older Adults. American Journal of Geriatric Psychiatry, 2008, 16, 813-818.	1.2	31
223	An Open-Label Pilot Study of Acetylcholinesterase Inhibitors to Promote Functional Recovery in Elderly Cognitively Impaired Stroke Patients. Cerebrovascular Diseases, 2008, 26, 317-321.	1.7	61
224	Do Clinical Rehabilitation Education Programs Really Improve Stroke-Related Knowledge?. American Journal of Physical Medicine and Rehabilitation, 2008, 87, 637-641.	1.4	6
225	Incomplete response in late-life depression: getting to remission. Dialogues in Clinical Neuroscience, 2008, 10, 419-430.	3.7	59
226	Rescue Pharmacotherapy With Duloxetine for Selective Serotonin Reuptake Inhibitor Nonresponders in Late-Life Depression. Journal of Clinical Psychiatry, 2008, 69, 457-463.	2.2	35
227	Recovery From Major Depression in Older Adults Receiving Augmentation of Antidepressant Pharmacotherapy. American Journal of Psychiatry, 2007, 164, 892-899.	7.2	97
228	Preventing Depression in Medical Illness. Archives of General Psychiatry, 2007, 64, 884.	12.3	14
229	Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. British Journal of Psychiatry, 2007, 190, 344-349.	2.8	164
230	Stroke-Related Knowledge and Health Behaviors Among Poststroke Patients in Inpatient Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2007, 88, 1214-1216.	0.9	44
231	Biomarkers in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2007, 15, 827-831.	1.2	9
232	Cognitive Impairment in Late-Life Generalized Anxiety Disorder. American Journal of Geriatric Psychiatry, 2007, 15, 673-679.	1.2	164
233	Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. International Journal of Geriatric Psychiatry, 2007, 22, 1141-1146.	2.7	43
234	Onset of Depression in Elderly Persons After Hip Fracture: Implications for Prevention and Early Intervention of Late-Life Depression. Journal of the American Geriatrics Society, 2007, 55, 81-86.	2.6	98

#	Article	IF	Citations
235	Maintenance Treatment for Oldâ€Age Depression Preserves Healthâ€Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy. Journal of the American Geriatrics Society, 2007, 55, 1325-1332.	2.6	50
236	Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients?. General Hospital Psychiatry, 2007, 29, 141-146.	2.4	61
237	Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders, 2007, 103, 77-82.	4.1	131
238	Maintenance Treatment of Major Depression in Old Age. New England Journal of Medicine, 2006, 354, 1130-1138.	27.0	408
239	Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life. American Journal of Geriatric Psychiatry, 2006, 14, 957-965.	1.2	25
240	Influence of Rehabilitation Site on Hip Fracture Recovery in Community-Dwelling Subjects at 6-Month Follow-Up. Archives of Physical Medicine and Rehabilitation, 2006, 87, 1004-1006.	0.9	14
241	The Relationship Between Pain and Mental Flexibility in Older Adult Pain Clinic Patients. Pain Medicine, 2006, 7, 444-452.	1.9	140
242	Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment. Journal of Clinical Psychiatry, 2006, 67, 468-472.	2.2	24
243	Dr. Lenze and Colleagues Reply. American Journal of Psychiatry, 2005, 162, 2196-2197.	7.2	0
244	Depression in the Elderly: The Unique Features Related to Diagnosis and Treatment. CNS Spectrums, 2005, 10, 1-4.	1.2	9
245	The Course of Functional Decline in Older People with Persistently Elevated Depressive Symptoms: Longitudinal Findings from the Cardiovascular Health Study. Journal of the American Geriatrics Society, 2005, 53, 569-575.	2.6	168
246	Comorbid anxiety disorder in late life depression: association with memory decline over four years. International Journal of Geriatric Psychiatry, 2005, 20, 848-854.	2.7	112
247	Somatic symptoms of depression in elderly patients with medical comorbidities. International Journal of Geriatric Psychiatry, 2005, 20, 973-982.	2.7	117
248	Somatic Symptoms in Late-Life Anxiety: Treatment Issues. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 89-96.	2.3	46
249	Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial. American Journal of Psychiatry, 2005, 162, 146-150.	7.2	114
250	Predictors of Adequacy of Depression Management in the Primary Care Setting. Psychiatric Services, 2005, 56, 1524-1528.	2.0	63
251	Combined Pharmacotherapy and Psychotherapy as Maintenance Treatment for Late-Life Depression: Effects on Social Adjustment. Focus (American Psychiatric Publishing), 2005, 3, 136-139.	0.8	0
252	Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2005, 13, 77-80.	1.2	81

#	Article	IF	Citations
253	Evidence-Based Treatment of Geriatric Anxiety Disorders. Psychiatric Clinics of North America, 2005, 28, 871-896.	1.3	88
254	Association of the Serotonin Transporter Gene-Linked Polymorphic Region (5-HTTLPR) Genotype With Depression in Elderly Persons After Hip Fracture. American Journal of Geriatric Psychiatry, 2005, 13, 428-432.	1.2	44
255	Effect of rehabilitation site on functional recovery after hip fracture. Archives of Physical Medicine and Rehabilitation, 2005, 86, 367-372.	0.9	83
256	Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2005, 13, 77-80.	1.2	57
257	Association of the Serotonin Transporter Gene-Linked Polymorphic Region (5-HTTLPR) Genotype With Depression in Elderly Persons After Hip Fracture. American Journal of Geriatric Psychiatry, 2005, 13, 428-432.	1.2	29
258	Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture. International Journal of Geriatric Psychiatry, 2004, 19, 472-478.	2.7	185
259	Time Course of Response to Antidepressants in Late-Life Major Depression. Drugs and Aging, 2004, 21, 531-554.	2.7	69
260	The Pittsburgh Rehabilitation Participation Scale: reliability and validity of a clinician-rated measure of participation in acute rehabilitation. Archives of Physical Medicine and Rehabilitation, 2004, 85, 380-384.	0.9	156
261	Significance of poor patient participation in physical and occupational therapy for functional outcome and length of stay. Archives of Physical Medicine and Rehabilitation, 2004, 85, 1599-1601.	0.9	101
262	Comorbidity of depression and anxiety in the elderly. Current Psychiatry Reports, 2003, 5, 62-67.	4.5	55
263	Good treatment outcomes in late-life depression with comorbid anxiety. Journal of Affective Disorders, 2003, 77, 247-254.	4.1	61
264	Poster 74. Archives of Physical Medicine and Rehabilitation, 2003, 84, E18.	0.9	2
265	Treatment Considerations for Anxiety in the Elderly. CNS Spectrums, 2003, 8, 6-13.	1.2	19
266	Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety. CNS Spectrums, 2003, 8, 27-34.	1.2	21
267	Anxiety Disorders in Late Life: An Evolving Picture. CNS Spectrums, 2002, 7, 805-810.	1.2	3
268	Combined Pharmacotherapy and Psychotherapy as Maintenance Treatment for Late-Life Depression: Effects on Social Adjustment. American Journal of Psychiatry, 2002, 159, 466-468.	7.2	92
269	Clinically Relevant Behaviors in Elderly Hip Fracture Inpatients. International Journal of Psychiatry in Medicine, 2002, 32, 249-259.	1.8	19
270	Anxiety Symptoms in Elderly Patients with Depression. Drugs and Aging, 2002, 19, 753-760.	2.7	28

#	Article	IF	CITATION
271	Effect of Cerebrovascular Risk Factors on Depression Treatment Outcome in Later Life. American Journal of Geriatric Psychiatry, 2002, 10, 592-598.	1.2	38
272	Physician office visits of adults for anxiety disorders in the United States, 1985–1998. Journal of General Internal Medicine, 2002, 17, 165-172.	2.6	67
273	Risk Factors for Falls During Treatment of Late-Life Depression. Journal of Clinical Psychiatry, 2002, 63, 936-941.	2.2	53
274	Effect of cerebrovascular risk factors on depression treatment outcome in later life. American Journal of Geriatric Psychiatry, 2002, 10, 592-8.	1.2	7
275	The Association of Late-Life Depression and Anxiety With Physical Disability: A Review of the Literature and Prospectus for Future Research. American Journal of Geriatric Psychiatry, 2001, 9, 113-135.	1.2	403
276	Comorbidity of depression and anxiety disorders in later life. Depression and Anxiety, 2001, 14, 86-93.	4.1	143
277	Subjective health measures and acute treatment outcomes in geriatric depression. International Journal of Geriatric Psychiatry, 2001, 16, 1149-1155.	2.7	37
278	Comorbid Anxiety Disorders in Depressed Elderly Patients. American Journal of Psychiatry, 2000, 157, 722-728.	7.2	292
279	White Matter Hyperintensities and Gray Matter Lesions in Physically Healthy Depressed Subjects. American Journal of Psychiatry, 1999, 156, 1602-1607.	7.2	88
280	Reactivation of Latent Herpes Simplex Virus by Excimer Laser Photokeratectomy. American Journal of Ophthalmology, 1992, 114, 45-50.	3.3	87
281	Electroencephalography-Guided Minimisation of Anaesthetic Administration to Prevent Post-Operative Delirium: A Randomised, Pragmatic Trial. SSRN Electronic Journal, 0, , .	0.4	0